News

The Pharma Letter54m
Biohaven wins $600 million investment from Oberland Capital
Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...
The Pharma Letter50m
Cost cuts factor into Q1 as Pfizer posts better-than-expected results
Pfizer reported first-quarter 2025 earnings on Tuesday that beat Wall Street expectations, boosted by ongoing cost-cutting ...